Washington Life Science Report – August 2020

LIFE SCIENCE WASHINGTON INSTITUTE

A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions

Washington State Transactions by Industry



Number of Deals per Sector

*As of 9/3/20



Monthly Highlights

HIGHLIGHTS

- **Athira Pharma** announced plans for an IPO, seeking to raise $100M, to fund further development of therapies to treat Alzheimer's Disease, Parkinson's Disease, or other neurodegenerative conditions. This is the first bio-tech IPO of 2020. Athira Pharma is a graduate of Life Science WA Institute's Washington Innovation Network (WIN) Mentoring Program. (Geekwire)
- **Nanodropper** announced receipt of a Phase II Small Business Innovation Research (SBIR) grant of $500,000. The company has previously received a Phase I contract. Standard eye drop bottles deliver more medication than the eye can physically absorb, resulting in medication waste. Nanodropper's FDA-approved adaptor fits to the top of standard eye drop bottles and is designed to reduce waste in the delivery of eye medication. Nanodropper participates in LSWI's WIN Mentoring Program and is a graduate of the UW Jones Foster Accelerator, Judge's Choice winner of the 2019 Life Science Innovation Northwest Fast Pitch Competition, and winner of the UW Holloman Health Innovation Challenge in 2019. (Geekwire)
- **Xealth,** a Seattle-based startup, announced a partnership and $6M investment from Cerner to help hospitals incorporate digital health programs. Xealth allows doctors and nurses to issue digital prescription such as apps and digital media. It can use patient data to recommend services from a variety of vendors for possible prescription, and routes this data from services back into the hospital's electronic health record. (Geekwire)

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.

Washington Life Science Report – August 2020

LIFE SCIENCE WASHINGTON INSTITUTE

Washington Life Science Transactions

Date	Company	Type	Amount
1/20/2020	Optimize.health	Equity	$3,500,000
1/23/2020	Athira Pharma	Convertible Debt	$3,830,000
1/29/2020	Ventec Life Systems	Equity	$24,030,000
1/31/2020	Twistle	Equity	$18,000,000
1/31/2020	Soovu Labs	Convertible Debt	$800,000
2/1/2020	ActX	Cash	$5,900,000
2/1/2020	Inmedix	ven	undisclosed
2/1/2020	Proteios Technology	Cash	undisclosed
2/11/2020	Cardiac Insight	Debt	$8,000,000
2/14/2020	Bardy Diagnostics	Cash	$12,490,000
2/18/2020	PharmID	Equity	$5,000,000
2/19/2020	CuraCloud	Cash	undisclosed
2/20/2020	Lupa Bio	Convertible Debt	undisclosed
2/21/2020	AVM Biotechnology	Equity	$2,570,000
2/24/2020	Selkirk Pharma	Equity	$9,050,000
2/25/2020	Oisin Biotechnologies	Equity	$2,970,000
2/26/2020	PVP Biologics		$3,300,000
2/27/2020	WellPepper	Equity	undisclosed
2/28/2020	Pacific Rim Outpatient Surgery Center		undisclosed
3/1/2020	Joylux	Cash	undisclosed
3/1/2020	LumniThera	Cash & Equity	undisclosed
3/1/2020	Nanodropper	Cash	$30,000
3/11/2020	Silverback Therapeutics	Equity	$78,500,000
3/11/2020	OtoNexus Medical Technologies	Equity	$9,700,000
3/19/2020	Concure Oncology	Cash & Equity	$7,750,000
3/20/2020	Medcurity	Cash & Equity	$737,500
3/26/2020	Novuson Surgical	Cash & Equity	$2,380,000
4/1/2020	YouScript	M&A	$79,300,000
4/1/2020	Sentinel Healthcare		undisclosed
4/1/2020	SCI Solutions	Cash	$190,000,000
4/2/2020	Blaze Bioscience	Cash & Equity	$23,230,000
4/2/2020	Rodeo Therapeutics	Equity	$8,950,000
4/3/2020	98point6	Cash	$43,000,000
4/6/2020	Juva for Migraine		$500,000
4/15/2020	SiDx	Convertible Debt	$1,250,000
4/21/2020	welcomehomehealth.com	Equity	$1,500,000
4/22/2020	Myosana Therapeutics	Cash	$1,000,000
4/26/2020	Avalyn	Cash	$35,500,000
5/5/2020	Kineta	Equity	$5,000,000
5/14/2020	LifeStance Health	Equity	$1,200,000,000
5/18/2020	Nautilus Biotechnology	Cash	$76,060,000
5/21/2020	Good Therapeutics	Cash	$22,340,000
5/22/2020	MDMetrix	Cash	$1,150,000
5/22/2020	Stratos Genomics		undisclosed
5/22/2020	Tasso	Cash	$17,000,000
5/27/2020	Alvaxa Biosciences		undisclosed
6/2/2020	eDoula	Convertible Debt	$50,000
6/3/2020	AIDA Healthcare	Convertible Debt	$515,000
6/4/2020	Kineta	Equity	$100,000
6/4/2020	Athira Pharma	Cash	$85,500,000
6/11/2020	Sana Biotechnology	Cash	$435,000,000
6/12/2020	MicrobiomX	Convertible Debt	$505,000
6/17/2020	Proprio	Cash	$23,000,000
6/22/2020	Oisin Biotechnologies	Equity	$5,090,000
6/24/2020	Modento	Equity	$1,000,000
7/8/2020	LumniThera	Cash	$14,000,000
7/13/2020	Ulcer Solutions	Equity	undisclosed
7/13/2020	Innovega	Equity	$2,140,000
7/21/2020	Curvafix	Equity	$10,750,000
7/22/2020	Magnolia Neurosciences	Equity	$5,000,000
8/4/2020	Proprio	Equity	$220,000
8/6/2020	Xealth	Equity	$6,000,000
8/10/2020	Variant Bio	Equity	$8,100,000
8/12/2020	MicroMend	Convertible Debt	$4,190,000
8/13/2020	Aminex Therapeutics	Convertible Debt	$2,870,000
8/20/2020	Optimize.health	Equity	$15,000,000
8/25/2020	Prescryptive	Equity	$26,000,000
8/27/2020	Deverra Therapeutics	Equity	$80,000
9/1/2020	Lumen Bioscience	Equity	$16,000,000
		Total	**$2,565,427,500**

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.
**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.